RESUMEN
In the present study, we examined the ability of Enterobacter cloacae Z0206 to reduce toxic sodium selenite and mechanism of this process. E. cloacae Z0206 was found to completely reduce up to 10 mM selenite to elemental selenium (Se°) and form selenium nanoparticles (SeNPs) under aerobic conditions. The selenite reducing effector of E. cloacae Z0206 cell was to be a membrane-localized enzyme. iTRAQ proteomic analysis revealed that selenite induced a significant increase in the expression of fumarate reductase. Furthermore, the addition of fumarate to the broth and knockout of fumarate reductase (frd) both significantly decreased the selenite reduction rate, which revealed a previously unrecognized role of E. cloacae Z0206 fumarate reductase in selenite reduction. In contrast, glutathione-mediated Painter-type reactions were not the main pathway of selenite reducing. In conclusion, E. cloacae Z0206 effectively reduced selenite to Se° using fumarate reductase and formed SeNPs; this capability may be employed to develop a bioreactor for treating Se pollution and for the biosynthesis of SeNPs in the future.
Asunto(s)
Enterobacter cloacae/metabolismo , Nanopartículas/química , Selenio/química , Selenito de Sodio/metabolismo , Aerobiosis , Enterobacter cloacae/enzimología , Oxidación-Reducción , Selenito de Sodio/química , Succinato DeshidrogenasaRESUMEN
BACKGROUND: Antibiotic resistance is an emerging phenomenon in kidney transplantation (KT). METHODS: We compared species distribution and antimicrobial susceptibility patterns in 1052 isolates from urine cultures obtained in 2 different cohorts of kidney transplant recipients in a single center (Cohort A: 189 patients undergoing KT between January 2002 and December 2004 [336 isolates]; Cohort B: 115 patients undergoing KT between January 2011 and December 2013 [716 isolates]). RESULTS: Asymptomatic bacteriuria accounted for most of the isolates (86.9% in Cohort A and 92.3% in Cohort B). Klebsiella pneumoniae (9.5% vs. 15.6%), Pseudomonas aeruginosa (1.8% vs. 7.9%), and Enterobacter cloacae (0.6% vs. 3.1%) were significantly more common in Cohort B. The isolation of K. pneumoniae in Cohort B was associated with the occurrence of acute pyelonephritis (9.8% of all K. pneumoniae isolates vs. 2.8% of the remaining uropathogens; P = 0.001). Non-susceptibility rates among Enterobacteriaceae in Cohort B were higher for every class of antibiotics (P ≤ 0.003) with the exception of fosfomycin. Compared to Cohort A, significant increases were seen in isolates from Cohort B for multidrug-resistant (MDR) (43.9% vs. 67.8%, respectively; P = 0.001), extended-spectrum beta-lactamase (ESBL)-producing (6.6% vs. 26.1%; P = 0.001), and carbapenemase-producing Enterobacteriaceae strains (0.0% vs. 5.0%; P = 0.001). Such differences were mostly attributable to K. pneumoniae (as 54.5% and 13.4% of isolates in Cohort B were ESBL-producing and carbapenemase-producing, respectively). MDR isolates were responsible for 69.1% of episodes of symptomatic urinary tract infection in Cohort B. CONCLUSION: The increase in resistance rates among Enterobacteriaceae uropathogens is significant and may have an effect on KT programs.
Asunto(s)
Antibacterianos/farmacología , Farmacorresistencia Bacteriana , Enterobacter cloacae/efectos de los fármacos , Infecciones por Enterobacteriaceae/microbiología , Trasplante de Riñón/efectos adversos , Infecciones Urinarias/microbiología , Adulto , Anciano , Antibacterianos/administración & dosificación , Antibacterianos/uso terapéutico , Infecciones Asintomáticas , Proteínas Bacterianas/metabolismo , Enterobacter cloacae/enzimología , Enterobacter cloacae/aislamiento & purificación , Infecciones por Enterobacteriaceae/tratamiento farmacológico , Infecciones por Enterobacteriaceae/orina , Femenino , Fosfomicina/administración & dosificación , Fosfomicina/farmacología , Fosfomicina/uso terapéutico , Humanos , Infecciones por Klebsiella/microbiología , Infecciones por Klebsiella/orina , Klebsiella pneumoniae/aislamiento & purificación , Masculino , Pruebas de Sensibilidad Microbiana , Persona de Mediana Edad , Infecciones por Pseudomonas/microbiología , Infecciones por Pseudomonas/orina , Pseudomonas aeruginosa/aislamiento & purificación , Ensayos Clínicos Controlados Aleatorios como Asunto , Estudios Retrospectivos , Infecciones Urinarias/tratamiento farmacológico , Infecciones Urinarias/orina , beta-Lactamasas/metabolismoRESUMEN
INTRODUCTION: Enterobacter cloacae is a pathogenic microorganism with the ability to produce betalactamase enzymes, which makes them resistant to betalactamic antibiotics. Additionally, the limited activity of enzymatic inhibitors has been identified, and, therefore, the design of new drugs and the promotion of their rational use are the only possibilities to overcome this problem. OBJECTIVE: The aim of this research was to evaluate the effect of dihydroxy-phenyl-propenone on a clinical isolate of E. cloacae , as well as its activity on a betalactamase isolated from this resistant microorganism in order to contribute to the search for new betalactamase inhibitors. MATERIALS AND METHODS: Dihydroxy-phenyl-propenone chalcone was synthesized and evaluated on a clinical isolate of E. cloacae to determine the minimum inhibitory concentration by broth microdilution; once the betalactamase enzyme was purified by affinity chromatography, a spectrophotometric analysis was done to evaluate its kinetic activity. RESULTS: The minimum inhibitory concentration value of dihydroxy-phenyl-propenone on E. cloacae was 35 µg/ml; the recovery percentage of the betalactamase from the microorganism was 31.75% and the kinetic parameters were V max =1.7 x 10 -3 µM/min and K M = 2330 µM, which show an important inhibitory activity. CONCLUSION: Dihydroxy-phenyl-propenone has shown inhibitory activity on betalactamase enzymes and the ability to protect the chemical integrity of betalactamic antibiotics; this synergistic effect turns it into a promising compound in the search for new alternatives to overcome bacterial resistance.
Asunto(s)
Proteínas Bacterianas/antagonistas & inhibidores , Chalconas/farmacología , Enterobacter cloacae/efectos de los fármacos , Penicilinasa/metabolismo , Resistencia betalactámica/efectos de los fármacos , Inhibidores de beta-Lactamasas/farmacología , Ampicilina/farmacología , Proteínas Bacterianas/aislamiento & purificación , Proteínas Bacterianas/metabolismo , Chalconas/síntesis química , Chalconas/química , Cromatografía de Afinidad , Recuento de Colonia Microbiana , Colorimetría , Evaluación Preclínica de Medicamentos , Sinergismo Farmacológico , Enterobacter cloacae/enzimología , Infecciones por Enterobacteriaceae/microbiología , Humanos , Pruebas de Sensibilidad Microbiana , Estructura Molecular , Ácido Penicilánico/análogos & derivados , Ácido Penicilánico/antagonistas & inhibidores , Penicilinasa/aislamiento & purificación , Tazobactam , Inhibidores de beta-Lactamasas/síntesis química , Inhibidores de beta-Lactamasas/químicaRESUMEN
Introducción . Los microorganismos patógenos como Enterobacter cloacae producen betalactamasas que les confieren resistencia frente a los antibióticos betalactámicos; se ha identificado, además, la actividad limitada de los inhibidores enzimáticos, de modo que la única posibilidad de enfrentar la resistencia es el diseño de nuevos fármacos y su uso racional. Objetivo. Evaluar el efecto de la chalcona dihidroxifenil propenona sobre un aislamiento clínico de E. cloacae y sobre la betalactamasa aislada a partir de este microorganismo resistente como un aporte en la búsqueda de compuestos inhibidores de las betalactamasas. Materiales y métodos. Se sintetizó la chalcona dihidroxifenil propenona y se evaluó su efecto sobre el aislamiento clínico de E. cloacae para determinar la concentración inhibitoria mínima mediante el método de microdilución en caldo y con la betalactamasa purificada mediante cromatografía de afinidad se realizaron estudios espectrofotométricos de cinética enzimática. Resultados. La concentración inhibitoria mínima de la dihidroxifenil propenona sobre E. cloacae fue de 35 µg/ml; el porcentaje de recuperación de la betalactamasa a partir del microorganismo fue de 31,75 %; en el estudio cinético se evidenció actividad inhibitoria de acuerdo con los parámetros cinéticos de V max =1,7 x 10 -3 µM/minuto y K M´ =2330 µM. Conclusión. La chalcona dihidroxifenil propenona ejerce su actividad inhibitoria por medio de la interacción con la betalactamasa y, de esta manera, protege la integridad estructural de los antibióticos betalactámicos; dicho efecto sinérgico la convierte en un compuesto promisorio en la búsqueda de alternativas para enfrentar la resistencia bacteriana.
Introduction: Enterobacter cloacae is a pathogenic microorganism with the ability to produce betalactamase enzymes, which makes them resistant to betalactamic antibiotics. Additionally, the limited activity of enzymatic inhibitors has been identified, and, therefore, the design of new drugs and the promotion of their rational use are the only possibilities to overcome this problem. Objective: The aim of this research was to evaluate the effect of dihydroxy-phenyl-propenone on a clinical isolate of E. cloacae , as well as its activity on a betalactamase isolated from this resistant microorganism in order to contribute to the search for new betalactamase inhibitors. Materials and methods: Dihydroxy-phenyl-propenone chalcone was synthesized and evaluated on a clinical isolate of E. cloacae to determine the minimum inhibitory concentration by broth microdilution; once the betalactamase enzyme was purified by affinity chromatography, a spectrophotometric analysis was done to evaluate its kinetic activity. Results: The minimum inhibitory concentration value of dihydroxy-phenyl-propenone on E. cloacae was 35 µg/ml; the recovery percentage of the betalactamase from the microorganism was 31.75% and the kinetic parameters were V max =1.7 x 10 -3 µM/min and K M = 2330 µM, which show an important inhibitory activity. Conclusion: Dihydroxy-phenyl-propenone has shown inhibitory activity on betalactamase enzymes and the ability to protect the chemical integrity of betalactamic antibiotics; this synergistic effect turns it into a promising compound in the search for new alternatives to overcome bacterial resistance.
Asunto(s)
Humanos , Proteínas Bacterianas/antagonistas & inhibidores , Chalconas/farmacología , Enterobacter cloacae/efectos de los fármacos , Penicilinasa/metabolismo , Resistencia betalactámica/efectos de los fármacos , Inhibidores de beta-Lactamasas/farmacología , Ampicilina/farmacología , Proteínas Bacterianas/aislamiento & purificación , Proteínas Bacterianas/metabolismo , Cromatografía de Afinidad , Recuento de Colonia Microbiana , Colorimetría , Chalconas/química , Chalconas/síntesis química , Evaluación Preclínica de Medicamentos , Sinergismo Farmacológico , Enterobacter cloacae/enzimología , Infecciones por Enterobacteriaceae/microbiología , Pruebas de Sensibilidad Microbiana , Estructura Molecular , Ácido Penicilánico/análogos & derivados , Ácido Penicilánico/antagonistas & inhibidores , Penicilinasa/aislamiento & purificación , Inhibidores de beta-Lactamasas/química , Inhibidores de beta-Lactamasas/síntesis químicaRESUMEN
Glucosinolates from the genus Brassica can be converted into bioactive compounds known to induce phase II enzymes, which may decrease the risk of cancers. Conversion via hydrolysis is usually by the brassica enzyme myrosinase, which can be inactivated by cooking or storage. We examined the potential of three beneficial bacteria, Lactobacillus plantarum KW30, Lactococcus lactis subsp. lactis KF147, and Escherichia coli Nissle 1917, and known myrosinase-producer Enterobacter cloacae to catalyze the conversion of glucosinolates in broccoli extract. Enterobacteriaceae consumed on average 65% glucoiberin and 78% glucoraphanin, transforming them into glucoiberverin and glucoerucin, respectively, and small amounts of iberverin nitrile and erucin nitrile. The lactic acid bacteria did not accumulate reduced glucosinolates, consuming all at 30-33% and transforming these into iberverin nitrile, erucin nitrile, sulforaphane nitrile, and further unidentified metabolites. Adding beneficial bacteria to a glucosinolate-rich diet may increase glucosinolate transformation, thereby increasing host exposure to bioactives.
Asunto(s)
Enterobacter cloacae/enzimología , Escherichia coli/enzimología , Glucosinolatos/metabolismo , Glicósido Hidrolasas/metabolismo , Lactobacillus/enzimología , Nitrilos/metabolismo , Brassica/química , Brassica/enzimología , Glucosa/análogos & derivados , Glucosa/metabolismo , Imidoésteres/metabolismo , Isotiocianatos/metabolismo , Lactobacillus plantarum/enzimología , Estrés Oxidativo , Extractos Vegetales/metabolismo , Sulfuros/metabolismo , Tiocianatos/metabolismoRESUMEN
The purpose of this investigation was to examine the antibacterial and synergistic effect of naturally occurring flavonoids, apigenin, quercetin, naringenin and ceftazidime when use singly and in combination against ceftazidime-resistant Enterobacter cloacae strains by minimum inhibitory concentration (MIC), checkerboard and viable count methods. The mode of actions were also studied by electronmicoscopy, enzyme assay, outer and inner membrane permeabilisation. The results showed that these strains were positive in the ESBL-ampC genes combination by multiplex PCR. These findings were confirmed by MICs that these strains were resistant to ceftazidime, cefepime and flomoxef at >1024, 16-24, >256 µg/ml respectively, while susceptible to imipenem at 1-2 µg/ml. The synergistic activity was observed at ceftazidime plus either apigenin or naringenin combinations with FIC indixes between <0.01 and <0.27 against these strains, whereas ceftazidime plus clavulanic acid or quercetin did not exhibit synergy. The modulation of ceftazidime-resistance by apigenin or narigenin significantly enhanced the activities of ceftazidime. The 5,7-OH group of A ring and one 4'-OH group of the B ring in apigenin and naringenin are important for synergistic activity. Viable counts showed that the killing of ceftazidime-resistant E. cloacae DMST 21394 (CREC) cells by 3 µg/ml ceftazidime was potentiated by 3 µg/ml apigenin to low levels (10(3) cfu/ml) over 6h. Electronmicroscopy clearly showed that ceftazidime 3 µg/ml in combination with 3 µg/ml of apigenin also caused marked morphological damage of cell wall, cell shape and plasma membrane of this strain. Enzymes assays indicated that apigenin showed marked inhibitory activity against penicillinase type IV from E. cloacae. The results for outer membrane (OM) permeabilization in both nitrocefin (NCF) assay and crystal violet uptake showed that the combination of ceftazidime plus apigenin significantly altered OM permeabilisation of CREC compared to control or single treatment of these agents. Both o-nitrophenyl-ß-D-galactoside (ONPG) uptake and release of UV-absorbing material concentrations results exhibited that ceftazidime and apigenin combination damaged CREC cytoplasmic membrane (CM) and caused subsequent leakage of intracellular constituents. From the results, it can be concluded that apigenin and naringenin have the synergistic effect with ceftazidime to reverse bacterial resistance to this cephalosporin against CREC. This activity may be involved three mechanisms of action by apigenin. The first is on the peptidoglycan synthesis inhibition. The second mechanism is inhibition the activity of certain ß-lactamase enzymes. The third mode of action is alteration of OM and CM permeabilization. Apigenin and naringenin have a sufficient margin of safety for therapeutic use. For this reason, apigenin and naringenin offer for the development of a valuable adjunct to ceftazidime against CREC, which currently almost cephalosporins resistance.
Asunto(s)
Antibacterianos/uso terapéutico , Apigenina/uso terapéutico , Ceftazidima/uso terapéutico , Enterobacter cloacae/efectos de los fármacos , Antibacterianos/farmacología , Antioxidantes/uso terapéutico , Apigenina/farmacología , Proteínas Bacterianas/genética , Proteínas Bacterianas/metabolismo , Ceftazidima/farmacología , Permeabilidad de la Membrana Celular/efectos de los fármacos , Sinergismo Farmacológico , Enterobacter cloacae/enzimología , Enterobacter cloacae/genética , Flavanonas/uso terapéutico , Pruebas de Sensibilidad Microbiana , Microscopía Electrónica de Transmisión , Fenotipo , Fitoterapia , Quercetina/uso terapéutico , beta-Lactamasas/genética , beta-Lactamasas/metabolismoRESUMEN
Class C ß-lactamases mediate antibiotic resistance in bacteria by efficiently hydrolyzing a broad range of ß-lactam antibiotics. With their clinical significance and the lack of commercially available effective inhibitors, development of class C ß-lactamase inhibitors has become one of the recent hot issues in the pharmaceutical industry. In this paper, we report the protein engineering of a fluorescent Amp C ß-lactamase mutant designated as V211Cf for the in vitro screening of class C ß-lactamase inhibitors. When a fluorescein (f) was incorporated at the entrance of the enzyme's active site (position 211), Amp C ß-lactamase from Enterobacter cloacae P99 was tailor-made into a novel fluorescent biosensing protein that could display a fluorescence enhancement upon binding with its ß-lactam substrates/inhibitors. With its catalytic activity close to the wild-type level, V211Cf can act as a "natural" fluorescent drug target for screening small binding molecules. In addition, V211Cf can allow specific detection for its active-site binding molecules and discriminate them from nondruglike molecules in the screen. Furthermore, V211Cf is amenable to a high throughput format. Taken together, V211Cf demonstrates the potential as an efficient tool for screening class C ß-lactamase inhibitors and facilitates the discovery of therapeutics that can combat the clinically important class C ß-lactamases.
Asunto(s)
Proteínas Bacterianas/antagonistas & inhibidores , Proteínas Bacterianas/genética , Evaluación Preclínica de Medicamentos/métodos , Inhibidores Enzimáticos/farmacología , Ingeniería de Proteínas , Inhibidores de beta-Lactamasas , beta-Lactamasas/genética , Antibacterianos/metabolismo , Antibacterianos/farmacología , Proteínas Bacterianas/química , Proteínas Bacterianas/metabolismo , Biocatálisis , Enterobacter cloacae/enzimología , Inhibidores Enzimáticos/metabolismo , Modelos Moleculares , Mutación , Conformación Proteica , Espectrometría de Fluorescencia , beta-Lactamasas/química , beta-Lactamasas/metabolismo , beta-Lactamas/metabolismo , beta-Lactamas/farmacologíaRESUMEN
The bioaugmentation of petroleum-contaminated soil using Enterobacter cloacae was profiled from the evolution of microbial community, soil dehydrogenase activity, to the degradation of petroleum contaminants. The seeding and proliferation of inoculant and the consequential microbial community were monitored by denaturing gradient gel electrophoresis analysis of the amplification of V3 zone of 16S rDNA. Degradation process kinetics was characterized by the degradation ratio of nC17 to nC18. The dehydrogenase activity was also determined during the degradation process. An abrupt change in the microbial community after inoculation was illustrated as well as successive changes in response to degradation of the petroleum contaminants. Seeding with E. cloacae stimulated the growth of other degrading stains such as Pseudomonas sp. and Rhodothermus sp. The application of wheat straw as a representative lignin waste, at 5% (w/w), induced an increase in the total dehydrogenase activity from 0.50 to 0.79, an increase in the microbial content of 130% for bacteria and 84% for fungi, and an increase of the overall degradation ratio from 44% to 56% after 56 days of treatment. The above mentioned results have provided a microbial ecological insight being essential for the design and implementation of bioaugmentation processes.
Asunto(s)
Enterobacter cloacae/enzimología , Hongos/enzimología , Consorcios Microbianos , Oxidorreductasas/metabolismo , Petróleo/metabolismo , Pseudomonas/enzimología , Rhodothermus/enzimología , Microbiología del Suelo , Biodegradación Ambiental , Recuento de Colonia Microbiana , Ecosistema , Electroforesis en Gel de Poliacrilamida , Enterobacter cloacae/crecimiento & desarrollo , Hongos/crecimiento & desarrollo , Lignina/metabolismo , Interacciones Microbianas , Oxidorreductasas/análisis , Pseudomonas/crecimiento & desarrollo , ARN Ribosómico 16S/análisis , Rhodothermus/crecimiento & desarrollo , Contaminantes del Suelo/metabolismo , Triticum/metabolismoRESUMEN
We have been using mutagenesis to determine how biocontrol bacteria such as Enterobacter cloacae 501R3 deal with complex nutritional environments found in association with plants. E. cloacae C10, a mutant of 501R3 with a transposon insertion in degS, was diminished in growth on synthetic cucumber root exudate (SRE), colonization of cucumber seed and roots, and control of damping-off of cucumber caused by Pythium ultimum. DegS, a periplasmic serine protease in the closely related bacterium Escherichia coli K12, is required for the RpoE-mediated stress response. C10 containing wild-type degS from 501R3 or from E. coli K12 on pBeloBAC11 was significantly increased in growth on SRE, colonization of cucumber roots, and control of P. ultimum relative to C10 containing pBeloBAC11 alone. C10 and 501R3 were similar in sensitivity to acidic conditions, plant-derived phenolic compounds, oxidative stress caused by hydrogen peroxide, dessication, and high osmoticum; stress conditions potentially associated with plants. This study demonstrates a role for degS in the spermosphere and rhizosphere during colonization and disease control by Enterobacter cloacae. This study implicates, for the first time, the involvement of DegS and, by extension, the RpoE-mediated stress response, in reducing stress on E. cloacae resulting from the complex nutritional environments in the spermosphere and rhizosphere.
Asunto(s)
Proteínas Bacterianas/fisiología , Cucumis sativus/microbiología , Enterobacter cloacae/enzimología , Enterobacter cloacae/genética , Mutagénesis Insercional/fisiología , Control Biológico de Vectores , Extractos Vegetales/farmacología , Pythium/patogenicidad , Secuencia de Aminoácidos , Proteínas Bacterianas/genética , Cucumis sativus/genética , ADN Bacteriano , Enterobacter cloacae/crecimiento & desarrollo , Escherichia coli/genética , Genes Bacterianos , Datos de Secuencia Molecular , Enfermedades de las Plantas/microbiología , Raíces de Plantas/microbiología , Pythium/crecimiento & desarrollo , Semillas/microbiología , Estrés FisiológicoRESUMEN
The aim of this study was to ascertain the incidence and clinical significance of metallo-beta-lactamases among Enterobacter strains isolated from patients with nosocomial infections. We prospectively collected data on patients with Enterobacter infection during a 13-month period. All of the strains were investigated for antibiotic susceptibility, the presence and expression of metallo-beta-lactamases, and clonality. Of 29 infections (11 involving the urinary tract, 7 pneumonias, 3 skin/soft tissue infections, 3 intra-abdominal infections, 3 bacteremias, and 2 other infections), 7 (24%) were caused by Enterobacter cloacae strains harboring a bla(VIM-1) gene associated or not with a bla(SHV12) gene. Infections caused by VIM-1-producing strains were more frequently associated with a recent prior hospitalization (P = 0.006), cirrhosis (P = 0.03), relapse of infection (P < 0.001), and more prolonged duration of antibiotic therapy (P = 0.01) than were other infections. All of the isolates were susceptible to imipenem and meropenem and had bla(VIM-1) preceded by a weak P1 promoter and inactivated P2 promoters. Most VIM-1-producing Enterobacter isolates belonged to a main clone, but four different clones were found. Multiclonal VIM-1-producing E. cloacae infections are difficult to diagnose due to an apparent susceptibility to various beta-lactams, including carbapenems, and are associated with a high relapse rate and a more prolonged duration of antibiotic therapy.